CRN Monthly Update for July 2015

In this issue:

Highlights

Grant and Manuscript Review Group

The CRN Publications Committee has been transformed into a Grant and Manuscript Review Group. This group aims to be supportive of people writing manuscripts and applications to enhance their likelihood of success and to ensure accuracy regarding the CRN. This group will review CRN-related manuscripts and grants for investigators who would like feedback on their manuscripts or proposals prior to submission. The review is not required, but is available to those who want to take advantage of it. Please refer to this documentExternal Web Site Policy for more details.

Opportunity Funds

The CRN continues to invite applications for Opportunity Fund Projects. This solicitation is focused specifically on support of activities that will result in submission of an R01 or similar application for grant funding. Applications are being accepted on a rolling basis. Successful applications may begin funding as early as Sept 1, 2015.

View the Information Packet (PDF, 390 KB) with more information about the Opportunity Fund, including who can apply, evaluation criteria, and more. Please note that the link to the online application has changedExternal Web Site Policy.

Upcoming Webinar: "Optimizing Survivorship and Decision Making in Low Risk Bladder Cancer"

Wednesday, July 15, 2015
10am PT/11am MT/1pm ET

Matt Nielsen, MD, will present "Optimizing Survivorship and Decision Making in Low Risk Bladder Cancer" at the July meeting of the Epidemiology of Prognosis & Outcomes SWG. Dr. Nielsen is Director of Urologic Oncology at the University of North Carolina Lineberger Comprehensive Cancer Center, where he is an Associate Professor of Urology and Adjunct Assistant Professor of Epidemiology and Health Policy & Management. In addition, he holds an appointment as a Clinical Investigator at the Center for Health Research at Kaiser Permanente Northwest (CHR-KPNW) in the CRN. Dr. Nielsen’s research program in decision making and cancer care quality dovetails with his active clinical practice focused in bladder and prostate cancer.

Open and join the webinarExternal Web Site Policy. Contact Sarah Madrid with any questions.

[Return to Top]

PopMedNet User Group Conference

Join us in Boston on July 27 and 28 for the PopMedNet User Group Conference. You’ll get a chance to help shape the open-source development of PopMedNet by interacting with users, developers, and network administrators across PopMedNet-based networks. These groups will demonstrate how they use PopMedNet to support a range of distributed research networks for comparative effectiveness research, medical product safety surveillance, and public health monitoring. We hope to see you there!

For more information and to purchase tickets, visit the event details pageExternal Web Site Policy.

For any other questions, please contact the event organizers: Zac Wyner, and Sarah Malek.

[Return to Top]

Welcome New Investigators

Gaia Pocobelli

The Informatics Core (IC) of the CRN would like to introduce Gaia Pocobelli, a Research Associate at Group Health Research Institute, who joined the IC in April of this year. Dr. Pocobelli earned her PhD in Epidemiology from the University of Washington and has experience in the fields of ovarian cancer, breast cancer screening, developing algorithms to detect second breast cancer events, and endometrial cancer risk related to pregnancy history. She completed a post-doctoral fellowship in reproductive epidemiology. Currently, she is leading QA efforts, cataloging CRN datasets, leading the chemotherapy infusion data utilization initiative and representing the IC on various VDW tumor workgroups. Welcome Dr. Pocobelli!

[Return to Top]

Recent Publications

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. JAMA 2015 Jun 16;313(23):2349-58. doi: 10.1001/jama.2015.6251. [View Abstract]

Thompson FE, Dixit-Joshi S, Potischman N, Dodd KW, Kirkpatrick SI, Kushi LH, Alexander GL, Coleman LA, Zimmerman TP, Sundaram ME, Clancy HA, Groesbeck M, Douglass D, George SM, Schap TE, Subar AF. Comparison of Interviewer-Administered and Automated Self-Administered 24-Hour Dietary Recalls in 3 Diverse Integrated Health Systems. Am J Epidemiol 2015 Jun 15;181(12):970-8. [View Abstract]

Carroll NM, Delate T, Menter A, Hornbrook MC, Kushi L, Aiello Bowles EJ, Loggers ET, Ritzwoller DP. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer. J Oncol Pract 2015 Jun 9. pii: JOP.2014.002980. [Epub ahead of print] [View Abstract]

Lafata JE, Salloum RG, Fishman PA, Ritzwoller DP, O'Keeffe-Rosetti MC, Hornbrook MC. Preventive care receipt and office visit use among breast and colorectal cancer survivors relative to age- and gender-matched cancer-free controls. J Cancer Surviv 2015 Jun;9(2):201-7. [View Abstract]

Chubak J, Hubbard RA, Johnson E, Kamineni A, Rutter CM. Assessing the effectiveness of a cancer screening test in the presence of another screening modality. J Med Screen 2015 Jun;22(2):69-75. [View Abstract]

Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of Diabetes among Patients Receiving Primary Androgen Deprivation Therapy for Clinically Localized Prostate Cancer. J Urol 2015 Jun;193(6):1956-62. [View Abstract]

Hillyer GC, Neugut AI. Where does it FIT?: The roles of fecal testing and colonoscopy in colorectal cancer screening. Cancer 2015 May 20. [Epub ahead of print] [Look up in PubMed]

Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL; Breast Cancer Surveillance Consortium. Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med 2015 May 19;162(10):673-81. doi: 10.7326/M14-1465. [View Abstract]

Weinmann S, Williams AE, Kamineni A, Buist DS, Masterson EE, Stout NK, Stark A, Ross TR, Owens CL, Field TS, Doubeni CA. Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007. Cancer 2015 May 18. [Epub ahead of print] [View Abstract]

Beaber EF, Kim JJ, Schapira MM, Tosteson AN, Zauber AG, Geiger AM, Kamineni A, Weaver DL, Tiro JA; Population-based Research Optimizing Screening through Personalized Regimens Consortium. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst 2015 May 7;107(6):djv120. Print 2015 Jun. [View Abstract]

[Return to Top]

Resource Reminder

Meetings and Calls for Abstracts

PopMedNet User Group ConferenceExternal Web Site Policy
Meeting date July 27 & 28, 2015 in Boston MA.

Translating Cancer Epidemiology: From Cells to Clinic and PopulationsExternal Web Site Policy
Abstracts due July 15, 2015. Meeting date Oct 23-35, 2015, Salt Lake City, UT.

AACR Conference on Advances in Breast Cancer ResearchExternal Web Site Policy
Abstracts due July 27, 2015. Meeting date October 17-20, 2015, Bellevue, WA.

AACR Conference on Advances in Ovarian Cancer Research: Exploiting VulnerabilitiesExternal Web Site Policy
Abstracts due Aug 3, 2015. Meeting date October 17-20, 2015, Orlando, FL.

Eighth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically UnderservedExternal Web Site Policy
Abstracts due Aug 6, 2015. Meeting date Nov 13-16, 2015, Atlanta, GA.

The Cancer Survivorship Symposium: Advancing Care and ResearchExternal Web Site Policy
Co-sponsored by American Academy of Family Physicians, the American College of Physicians, and the American Society of Clinical Oncology.
Abstracts due Sept 1, 2015. Meeting date Jan 15-16, 2016, San Francisco, CA.

[Return to Top]

Funding Opportunities

AACR NextGen Grants for Transformative Cancer ResearchExternal Web Site Policy
LOI due Aug 10, 2015

These three-year grants of $450,000 represent a new AACR funding initiative to stimulate highly innovative research from young investigators. Eligibility is limited to junior faculty who have held a full-time, tenure-track appointment as an assistant professor for no more than three years. The letter of intent deadline is August 10, 2015 at noon, EST.

Multidisciplinary Studies of HIV/AIDS and Aging - R01, R03, R21
Standard AIDS-related grant submission due dates (Sep 7, Jan 7, May 7)

NCI as a participating institute seeks to foster research studies to help understand how aging in the presence of chronic HIV infection affects the risk, spectrum and biology of cancer (AIDS-defining and non-AIDS-defining cancers). Recent data indicates an increase in the non-AIDS-defining cancers that is driven to a large extent by the growth and aging of the HIV/AIDS population. Aging is by itself a key factor promoting the development of many cancers, and there is a lack of data on the interplay between aging, HIV, long-term exposure to antiretroviral drugs, and other factors promoting cancer development in the aging population. In addition, there is little understanding of the interplay between host factors and immune perturbations that occur in aging and how these interactions affect cancers that are mostly seen in older people (e.g., Kaposi's sarcoma and Merkel cell carcinoma).

Pancreatic Cancer Detection Consortium - U01
Application Due Dates Nov 25, 2015, May 26, 2016, and others.

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention.

[Return to Top]

Copyright © 2015 The Cancer Research Network, All rights reserved.